CDMO Benchmarking Report
A trend analysis 2016-2018
CDMO Benchmarking Report
A trend analysis 2016-2018
SINGLE USER LICENCE(only view)
$5000.00
CORPORATE USER LICENCE(to be downloaded)
$10000.00
HARD COPY(to be shipped)
$7000.00
Author:
Advitech NEW report is focused on the latest trends in the global Contract Development and Manufacturing Organization (CDMO) market.
CDMO business models continue to evolve with CDMOs seeking to offer differentiated services or technologies, adding drug-product capabilities to existing small-molecule API expertise, or increasing investment in specialized technologies, such as high-potency manufacturing. The report details key differentiating technologies and services.
The report shows also several important trends in terms of pharmaceutical industry performance, drug development and recent new drug approvals, and the impact on the contract development and manufacturing (CDMO) market.
The focus of this analysis was to specifically examine the position of small-molecule drugs in the overall pharmaceutical market, drug development, and the impact on the strategy and business activity of CDMOs serving the small-molecule API space.
Last year Advitech selected a panel of 27 companies within the previous Baseline Analysis focused on 2016 data. These companies were chosen due to the following:
their well-established role as CMO/CDMO players;
headquarters in Europe or in US and the best-in-class companies in Asia;
and small-molecule API capabilities.
Now, with an unprecedented approach in our industry, Advitech has performed a three-year update of the same panel of companies that were considered in the Baseline Analysis as service providers in the CDMO sector for small-molecule APIs.
In a relatively short time frame, the panel has now evolved through mergers and acquisitions and rebranding activities into a new group of companies
All the companies in the panel offer specific expertise in the development and the production of small- molecule APIs.
The 28 panel companies.
All the companies in the panel offer specific expertise in the development and the production of small- molecule APIs.
Company
Headquarters (HQ)
Aesica
UK
Alcami
USA
Almac
UK
AMRI
USA
Cambrex
USA
Cerbios
Switzerland
Dipharma
Italy
Dottikon ES
Switzerland
Dr.Reddy's
India
Esteve Quimica
Spain
Fareva API only
Luxembourg
FIS
Italy
Flamma
Italy
Helsinn Advanced Synthesis
Switzerland
Hovione
Portugal
Jubilant
India
Lonza
Switzerland
Minakem-Minafin
Belgium
Novasep
France
Olon
Italy
Orion - Fermion
Finland
Procos
Italy
Recipharm
Sweden
Siegfried
Switzerland
Seqens
France
SK Holdings
Korea
Thermo Fisher - LPSS
USA
WuXi AppTec
China
The new data from the panel companies are shedding more light on the latest trends, and more factual evidence has been collected, in order to support Advitech trend analysis.
As expected, companies with the ability of spotting and understanding new trends within our industry and looking at the "big picture" from the popular "30,000-foot altitude" can also greatly benefit from the opposite approach, with a "zoom in" into their specific areas of interest and competence.
The combination of both approaches can provide powerful insights for both strategic and tactical evaluations of each business segment.
The Pharmaceutical Industry and the latest trends in the API segment [Zoom OUT]
Benchmarking of CDMO companies active in small-molecule APIs [Zoom IN]
The Pharmaceutical Industry in 2018
The Pharmaceutical Global Outlook
How many small-molecule APIs are in the world?
Global performance of small-molecules vs biologics: the 30 top-selling drug products
INCREASE
DECREASE
The pharmaceutical industry trends from the three-year update
The 30 top-selling drug products: three-year trend performance of small-molecules vs biologics:
The perceived growth rate in the 2016-2018 timeframe.
Investments, Expansions and Acquisitions within the CDMO Panel: the Three-year TREND
Copycat investments or following the market need?
The latest technologies in the pharmaceutical industry
Artificial Intelligence in Organic Chemistry
Robotic automation in pharma and chemistry industries
New trends in the supply-chain network
Drug Shortages: the FDA and EMA Task Forces
Growth opportunities in the fine-chemicals sector: API starting materials, EMA publishes updated reflection paper
New Trends in pharmaceutical service business models: full-service providers and the rise of Giga-CDMOs
Full-service providers
The rise of Giga-CDMOs
The evolution of small-molecules:
Small-molecules vs biologics in New Drug Approvals: the 2011-2018 TREND
New Trends in Orphan Drugs: smaller volumes of APIs needed for recently launched drugs / drugs to be launched in the future
The evolution of new Orphan Drugs since 2011:
Summary of the pharmaceutical industry trends from the 3-year update
Benchmarking of CDMO companies active in small-molecule APIs: the 3-year update
Benchmarking of CDMO companies: evolution of the 2016 data baseline
The new panel companies
The new tools
Size and Geography
Corporate structure and models of business: the 3-year trend
Finance and Business Model three-year trend analysis by segment (ZOOM OUT)
Finance and Business Model three-year trend analysis by company (ZOOM IN)
Global footprint, employees and API reactor capacity: the 3-year trend analysis
Service portfolio and scale capabilities
Technical capabilities: chemistry
Hazardous chemistry capabilities
Technical capabilities: drug products
Growth, investment and innovation: the 3-year update
Competitive advantage and stress absorption
Quality and Regulatory
Company snapshots: the 3-year update
Table of Figures
Bibliography
Author biography
Appendix
Paolo Magrì
Paolo Magrì is Senior Vice President Business Development at Advitech Advisory and Technologies. He has been elected to serve for a second term as President of the US Drug Chemical & Associated Technologies Association (DCAT).
Mr. Magrì has over 28 years of experience in the active pharmaceutical ingredient (API) sector. Prior to joining Advitech, he served as Vice President of Business Development at Infa Group. During his tenure (2005-2016), Infa grew by acquisition to include sites in Italy and Spain, and a contract manufacturing division. Prior to Infa, Mr Magrì served as Marketing and Sales Director at Sicor and in Teva's API division, after the acquisition of Sicor in 2003. His strong track record in the industry also includes previous roles at Archimica/Pro.Bio.Sint. and Fordras. Mr Magrì earned his master's degree in Chemistry and Pharmaceutical Technology from the University of Milan, Italy.